Meeting
2015 ASCO Annual Meeting
Prognostic impact of HER2 overexpression/amplification in women with pT1a N0 M0 breast cancer with known screening status: First results from a multicenter population-based cancer registry study.
Authors
Antonino Musolino
Medical Oncology Unit, University Hospital of Parma, Parma, Italy
Antonino Musolino , Maria Michiara , Daniela Boggiani , Angelica Sikokis , Anita Rimanti , Benedetta Pellegrino , Eugenia Martella , Francesco Bozzani , Paolo Sgargi , Michele Panebianco , Giancarlo Bisagni , Fabio Falcini , Carmine Pinto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Citation
J Clin Oncol 33, 2015 (suppl; abstr 594)
DOI
10.1200/jco.2015.33.15_suppl.594
Abstract #
594
Poster Bd #
83
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Prognostic role of HER2 loss after neoadjuvant therapy in patients with HER2-positive operable breast cancer.
First Author: Valentina Guarneri
Poster
2012 ASCO Annual Meeting
Estrogen receptor in HER2-positive early breast cancer: Two different diseases?
First Author: Eva Maria Ciruelos Gil
Poster
2021 ASCO Annual Meeting
Phase II prospective open label study of neoadjuvant pertuzumab, trastuzumab, and nab-paclitaxel in patients with HER-2 positive advanced breast cancer.
First Author: Sayeh Moazami Lavasani
Poster
2019 ASCO Annual Meeting
Is neratinib following trastuzumab in early-stage HER2-positive breast cancer cost-effective?
First Author: Naomi RM Schwartz